Premier Biomedical Stock Cash And Equivalents
| BIEI Stock | USD 0.0006 0.0001 14.29% |
Premier Biomedical fundamentals help investors to digest information that contributes to Premier Biomedical's financial success or failures. It also enables traders to predict the movement of Premier Pink Sheet. The fundamental analysis module provides a way to measure Premier Biomedical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Premier Biomedical pink sheet.
Premier |
Premier Biomedical Company Cash And Equivalents Analysis
Premier Biomedical's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Premier Biomedical Cash And Equivalents | 71.2 K |
Most of Premier Biomedical's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Premier Biomedical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Premier Biomedical has 71.2 K in Cash And Equivalents. This is 99.99% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The cash and equivalents for all United States stocks is 100.0% higher than that of the company.
Premier Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Premier Biomedical's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Premier Biomedical could also be used in its relative valuation, which is a method of valuing Premier Biomedical by comparing valuation metrics of similar companies.Premier Biomedical is currently under evaluation in cash and equivalents category among its peers.
Premier Fundamentals
| Return On Asset | -1.54 | |||
| Operating Margin | (22.88) % | |||
| Current Valuation | 1.6 M | |||
| Shares Outstanding | 999.98 M | |||
| Shares Owned By Insiders | 2.36 % | |||
| Price To Earning | 0.07 X | |||
| Price To Sales | 112.03 X | |||
| Revenue | 14.28 K | |||
| Gross Profit | 1.42 K | |||
| EBITDA | 20.91 K | |||
| Net Income | (374.47 K) | |||
| Cash And Equivalents | 71.2 K | |||
| Total Debt | 160.75 K | |||
| Debt To Equity | (1.18) % | |||
| Current Ratio | 0.05 X | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (344.18 K) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 11 | |||
| Beta | -4.63 | |||
| Market Capitalization | 4.3 M | |||
| Total Asset | 100.94 K | |||
| Retained Earnings | (3.91 M) | |||
| Working Capital | (279.97 K) | |||
| Current Asset | 44.58 K | |||
| Current Liabilities | 324.55 K | |||
| Z Score | -40.0 | |||
| Net Asset | 100.94 K |
About Premier Biomedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Premier Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Premier Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Premier Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Premier Pink Sheet
Premier Biomedical financial ratios help investors to determine whether Premier Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Premier with respect to the benefits of owning Premier Biomedical security.